La vendita allo scoperto per Kyverna Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Kyverna Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Kyverna Therapeutics (NASDAQ:KYTX) Azioni, Report sulle vendite allo scoperto

Kyverna Therapeutics

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

KYTX

PSFE

RMBL

I titoli da tenere d&#39;occhio oggi: Home Depot, RumbleOn, Paysafe, Kyverna Therapeutics e XP Inc. nel pre-market.

Pre-market: 5 titoli da monitorare oggi, 13 agosto 2024

During Conf Call, JP Morgan Chase CFO Reportedly Says Inorganic Growth Is On The Table; Acquisitions Have A High Bar Both Financially And Strategically; It Is Difficult To Imagine A Large Deal That Would Make Sense For Us When It Comes To Inorganic Opportunities; It Is Difficult To Imagine A Large Deal That Would Make Sense For Us When It Comes To Inorganic Opportunities

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is trading around $117,000 after a brief pullback from its all-time high, with on-chain and technical indicators painting a complex picture of bullish momentum tempered by looming <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46412151/why-did-bitcoin-ethereum-xrp-dogecoin-flip-bearish-ahead-of-the-cpi-inflation-data-release">profit-taking pressure</a>.
What Happened: According to blockchain analytics firm Glassnode and technical research firm Fairlead Strategies, recent developments suggest Bitcoin&#8217;s uptrend remains intact, but not without warning signs.
Glassnode's latest weekly report <a href="https://x.com/glassnode/status/1944805339976622325">reveals</a> that nearly 99% of all Bitcoin supply is now in profit, a historically rare event.
"There are few precedents where this many holders are in profit, and in past cycles, this tends to coincide with a rising tendency for profit realization," the firm wrote.
The report also highlights a surge in short-term holder profits and unrealized gains nearing previous cycle peaks. 
"When short-term holders are this deep in profit, there is an elevated risk of sell-side pressure," Glassnode added.
Technical analysis from Fairlead Strategies reinforces a bullish outlook. 
"After several weeks of consolidation, Bitcoin has decisively cleared final resistance, resuming its cyclical and secular uptrends in a bullish long-term development," wrote analysts Katie Stockton and Will Tamplin. 
They project a "realistic intermediate-term objective" of approximately $134,500, citing reaccelerating momentum and positive weekly indicators.
Support levels are currently defined at $108,300 and $97,100, according to the Fairlead report. 
The analysis noted that "the MACD is long-term bullish" and the breakout has "affirmed the cyclical uptrend."
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46351536/you-can-stake-ethereum-solana-on-robinhood-but-is-it-worth-the-25-cut">You Can Stake Ethereum, Solana On Robinhood—But Is It Worth The 25% Cut?</a>
Why It Matters For Ethereum: Meanwhile, the Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) breakout has gained steam, with ETH recently pushing above $3,000.
"Ether has a confirmed breakout above its 200-day MA… The weekly MACD has shifted positive, and the weekly stochastics have a bullish ‘pop'," Fairlead wrote. 
The firm notes resistance at $3,070–$3,100 and a long-term upside potential tied to 2024 highs around $4,000, assuming follow-through continues.
Glassnode's report also notes a divergence in demand across wallet cohorts. 
While smaller holders continue to accumulate, larger wallets, particularly those holding more than 1,000 BTC, have shown "muted" growth. 
Whale activity on exchanges has increased as well. 
"The Accumulation Trend Score has fallen sharply… suggesting a softening in aggregate demand," Glassnode stated.
Relative strength among altcoins is also shifting, according to Fairlead's Relative Rotation Graph. 
Stellar (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xlm/usd">XLM</a>), Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), and Hedera (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/hbar/usd">HBAR</a>) have shown improving trajectories versus Bitcoin, while Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) and Avalanche (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/avax/usd">AVAX</a>) have weakened. 
"Ripple… has pushed out of a triangle pattern on renewed intermediate-term momentum," the report observed.
At the time of writing, Bitcoin is trading down 4% for the day at $116,880, approximately 5% below its all-time high above $123,000 seen yesterday.
Ethereum is trading around $2,980, down about 2.5% on the day.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46348745/crypto-users-prioritize-investment-education-over-consumption-nexo-report-finds">Crypto Users Prioritize Investment, Education Over Consumption, Nexo Report Finds</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$AVAX

$BTC

$ETH

$HBAR

$SOL

$XLM

$XRP

99% Of Bitcoin Holders Are In Profit: Is BTC Dipping Because Some Are Cashing Out?

Morgan Stanley analyst Michael Cyprys maintains Virtu Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NYSE">VIRT</a>) with a Underweight and raises the price target from $31 to $35.

Price Target

Analyst Ratings

VIRT

Morgan Stanley Maintains Underweight on Virtu Finl, Raises Price Target to $35

Barclays analyst Richard Hightower maintains Camden Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPT#NYSE">CPT</a>) with a Overweight and raises the price target from $136 to $137.

Barclays Maintains Overweight on Camden Prop Trust, Raises Price Target to $137

Morgan Stanley analyst Michael Cyprys maintains MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) with a Overweight and lowers the price target from $283 to $274.

MKTX

Morgan Stanley Maintains Overweight on MarketAxess Holdings, Lowers Price Target to $274

SSII

SS Innovations Installs Over 100 SSi Mantra Surgical Robotic Systems In India And Six Other Countries; Expects To Submit De Novo Application For Approval To Market SSi Mantra To FDA By July 2025 End For Multiple Indications

Barclays analyst Brandt Montour maintains B&amp;G Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) with a Equal-Weight and lowers the price target from $5 to $4.

Barclays Maintains Equal-Weight on B&G Foods, Lowers Price Target to $4

Morgan Stanley analyst Michael Cyprys maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Equal-Weight and raises the price target from $75 to $86.

NDAQ

Morgan Stanley Maintains Equal-Weight on Nasdaq, Raises Price Target to $86

The June inflation report brought a dose of relief to Wall Street on Tuesday morning, as the headline Consumer Price Index (CPI) matched expectations, while core inflation came in slightly cooler than forecast, reviving optimism for interest rate <a href="https://www.benzinga.com/topic/interest-rates">cuts later this year.</a>
The headline CPI rose 0.3% month over month and 2.7% year over year, exactly in line with the consensus. That marks an acceleration from May's 2.4% annual rate and the fastest price increase since January.
But the real surprise came from the core readings. Core CPI, which excludes food and energy, rose just 0.2% on the month and 2.9% annually, compared to expectations of 0.3% and 3.0%, respectively. 
While still elevated, the softer print gave markets a reason to believe the inflation uptrend might be more contained than feared.
The food index rose 0.3% for the second consecutive month, continuing to put pressure on consumer wallets. Grocery prices also rose 0.3%. Coffee jumped 2.2% in June, while citrus fruits climbed 2.3%. Beef prices also edged up 2%, though egg prices plunged by 7.4%
Energy prices also rebounded. After a drop in May, the energy index rose 0.9% in June. Gasoline prices increased 1.0%, electricity prices also climbed 1.0%, and natural gas edged up 0.5%. However, looking at the year-over-year numbers, gasoline prices are still down 8.3%, while electricity and natural gas prices are up 5.8% and 14.2%, respectively.
Some relief came from categories that had previously driven inflation. Used cars and trucks dropped 0.7% in June, adding to May's 0.5% decline, while new vehicle prices slipped 0.3%. Lodging away from home saw a sharp 2.9% decrease, and airline fares were down 0.1%.
Shelter was still up a firm 3.8% year over year. Other notable annual gains include a 6.1% increase in motor vehicle insurance, 3.3% for household furnishings and operations, and 2.8% for medical care.
<h2 class="wp-block-heading">Market Reactions</h2>
Markets welcomed the data with a cautious sense of relief. Futures on the S&amp;P 500 rose 0.4%, while contracts on the tech-heavy Nasdaq 100 jumped 0.7%, putting both major indexes on track to open at fresh record highs.
In the bond market, Treasury yields slipped, with the 10-year yield easing to 4.43%. Fed funds futures held steady, continuing to fully price in two rate cuts totaling 50 basis points by the end of 2025.
Gold, as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), was flat on the day. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46410553/us-stock-futures-trade-mixed-ahead-of-june-inflation-print-big-banks-in-focus-as-street-awaits-jpmorgan-wells-fargo-bny-mellon-citibanks-earnings">US Stock Futures Trade Mixed Ahead Of June Inflation Print: Big Banks In Focus As Street Awaits JPMorgan, Wells Fargo, BNY Mellon, Citibank&#8217;s Earnings </a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

Macro Economic Events

Economics

June Inflation Lands As Expected — But Cooler Core Reading Fuels Fed Rate Cut Hopes

Barclays analyst Richard Hightower maintains AvalonBay Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>) with a Equal-Weight and raises the price target from $240 to $241.

Barclays Maintains Equal-Weight on AvalonBay Communities, Raises Price Target to $241

Morgan Stanley analyst Michael Cyprys maintains Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) with a Underweight and raises the price target from $215 to $218.

CBOE

Morgan Stanley Maintains Underweight on Cboe Global Markets, Raises Price Target to $218

Barclays analyst Jiong Shao maintains Alibaba Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) with a Overweight and lowers the price target from $180 to $145.

BABA

Barclays Maintains Overweight on Alibaba Gr Hldgs, Lowers Price Target to $145

Morgan Stanley analyst Michael Cyprys maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Overweight and raises the price target from $83 to $117.

SCHW

Morgan Stanley Maintains Overweight on Charles Schwab, Raises Price Target to $117

Acme United Corp Purchases Manufacturing And Distribution Center In Mt. Pleasant, Tennessee For ~$6M

Morgan Stanley analyst Michael Cyprys maintains Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) with a Equal-Weight and raises the price target from $136 to $180.

Morgan Stanley Maintains Equal-Weight on Raymond James Finl, Raises Price Target to $180

Morgan Stanley analyst Michael Cyprys maintains LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) with a Overweight and raises the price target from $450 to $490.

LPLA

Morgan Stanley Maintains Overweight on LPL Finl Hldgs, Raises Price Target to $490

New model drives cost-effective, on-demand scalability to accelerate AI outcomes
NEW YORK, July 15, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4468301-1&amp;h=2315532518&amp;u=https%3A%2F%2Fwww.endeavourii.com%2F&amp;a=Endeavour+Energy+LLC">Endeavour Energy LLC</a> (Endeavour), a full-stack data center infrastructure technology developer, and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4468301-1&amp;h=2043395607&amp;u=https%3A%2F%2Fwww.jabil.com%2F&amp;a=Jabil">Jabil</a> <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4468301-1&amp;h=3717807871&amp;u=https%3A%2F%2Fwww.jabil.com%2F&amp;a=Inc.">Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>), a global leader in engineering, supply chain, and manufacturing, today announced an expanded collaboration to deliver modular, just-in-time (JIT) AI-ready infrastructure.
Endeavour and Jabil have collaborated on more than a dozen Edged data centers currently operational or under construction across North America and Europe. The new just-in-time platform will launch in the United States in Q1 2027.

Endeavour Energy And Jabil Announce Expanded Collaboration To Deliver Modular, Just-In-Time AI-Ready Infrastructure

Morgan Stanley analyst Michael Cyprys maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Equal-Weight and raises the price target from $43 to $110.

HOOD

Morgan Stanley Maintains Equal-Weight on Robinhood Markets, Raises Price Target to $110

Comscore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>), a global leader in measuring and analyzing consumer behaviors, today announced a multi-year partnership with HyphaMetrics, a Data-as-a-Service (DaaS) company transforming the media industry's understanding of what the world is watching. Once live, this data partnership and technology integration will expand Comscore's cross-platform measurement capabilities, introducing new CTV program-level reporting and delivering greater granularity to meet the growing demands of the programmatic streaming landscape.
The partnership intends to enhance Comscore's proprietary industry personification methodology by leveraging HyphaMetrics' proprietary ‘Unified Individual Media Metric', a unified view of audience behavior across every monitored screen and streaming platform within a household. This includes deterministic Viewers-per-Viewing-Household data and person-level co-viewing insights across devices. Comscore's personification approach transforms household-level viewing data into a more precise understanding of the individuals behind the screens, bringing new precision to both linear and CTV audience measurement.

SCOR

Comscore Announces Multi-Year Partnership With HyphaMetrics To Launch Person-Level Audience Measurement And CTV Program-Level Reporting

Morgan Stanley analyst Michael Cyprys downgrades Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) from Equal-Weight to Underweight and raises the price target from $462 to $530.

Downgrades

Morgan Stanley Downgrades Ameriprise Finl to Underweight, Raises Price Target to $530

Legal

Press Releases

Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf

Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT)

Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Kyverna Therapeutics

Vendite allo scoperto

Kyverna Therapeutics (NASDAQ:KYTX) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO